Systems and methods are described for treatment of neurological conditions in which transcranial illumination using infrared, near-infrared and/or red wavelengths of light are delivered into the brain of a patient using a portable head wearable device. Systems and methods are also described to deliver light to patient tissues for photobiomodulation, particularly through the patient's mouth.

In certain embodiments a light therapy system (e.g., phototherapy device), such as for treatment of Alzheimer's disease, depression, dementia, short-term memory, or for improved learning, improved athletic performance or improved cognitive performance, is provided where the light system comprises a blue light source that operates at a frequency in the range from 20 to 50 Hz (preferably around 40 Hz), whereby the system enables retinal ganglion cells of a human to be exposed in order to stimulate brain waves (gamma oscillations in the human's brain).

The present invention involves a programmable or static multiwavelength LED lighting fixture that is capable of emitting wavelengths of light both for visual perception and other key physiological processes. The lighting fixture produces emitted spectra, wherein one portion of the emitted spectra serves visual perception and at least one portion of the emitted spectra is selected from the group consisting of 290-315 nm; 360-400 nm; 470-490 nm; and 600-1400 nm.

The present disclosure relates to systems, methods, and uses of systems for treating a skin condition with phototherapy. A system comprises (a) a phototherapy device comprising a phototherapy light source; (b) a patient computing device comprising a processor and a memory, the patient computing device configured to: transmit a first signal to the phototherapy device enabling operation of the phototherapy device according to one or more conditional prescription parameters, activate the phototherapy light source, and transmit a second signal reporting operation of the phototherapy device; and (c) a server configured to communicate with the patient computing device and receive the second signal.

A computerized method for controlling the operation of a laser therapy device is disclosed. A laser therapy device comprising laser diodes has a microprocessor for storing and executing instructions pertaining to the operation of the laser diodes within certain parameters. The computerized method detects the movement of the laser therapy device and alters the output of the laser diodes when a movement signal exceeds predetermined threshold parameters. The computerized method detects difference in temperature in certain areas, and patterns in temperature differences, for assistance in diagnosing ailments. The computerized method also detects differences in skin color to determine treatment areas. The computerized method also measures the distance of the laser therapy device to a treatment area. The microprocessor executes instructions then which can alter the output of the laser diodes or generate an alarm signal based on measurements received.

Gamma brain stimulation (around 40 Hz) is performed using light pulses. To perform theta brain stimulation (around 7 Hz) without perceptible flicker, the light source is also strobed at 47 Hz (also within the gamma range). The brain perceives the 40 Hz and a subtraction frequency of 7 Hz (in the theta range). The combined gamma and theta wave stimulation of the brain may be used for preventing or treating brain disease or sleeping disorders. The particular stimulation frequencies and their phases create neuronal gamma-theta coupling in the brain that has been shown to have positive effects on memory, Alzheimer's disease, motor skills, and other functions. Other gamma and theta frequencies, creating gamma-theta coupling in the brain, are also beneficial. The phase of the light pulses is also dynamically controlled using feedback to maximize theta-gamma coupling in the brain.

Disclosed is a device for interstitial laser therapy. The device comprises an optical waveguide extending about a central longitudinal axis and having an optical output end; an optical diffuser optically coupled to, optically associate with, or positioned about the optical output end, wherein the optical diffuser comprises a housing having an open end for receiving the optical output end and a first longitudinal portion of the optical waveguide; and a temperature sensor interposed, positioned or located between the central longitudinal axis and an exterior surface of the housing, and preferably within the longitudinal extent of the first longitudinal portion of the optical waveguide. The optical diffuser can be provided with one or more holes, one or more slits, one or more openings, and/or one or more vents. The device can also include a second temperature sensor. Also disclosed is a system for interstitial laser therapy.

The present wireless remote control device is a type of equipment with non-tethered optical stimulation. The characteristic of this device is designed to utilize a magnetic resonance technique to modify the deficits of the conventional magnetic induction or radio-frequency power source. Compared to the other devices of photostimulation, the advantages are as follow: there is a strong and even electromagnetic power; the cost is cheaper than the previous others; the device uses the receiver coil on an animal's head to receive the magnetic power from the transformation of the electrical power in the outside big coil, and thus the weight of the receiver coil on the head is very light. The light and miniaturized coil on the head without battery could give animals more convenience in freely movement, and the behavior of animals can be controlled by the effective extent of the electromagnetic field through photostimulation.

Methods of the present invention comprise photoinactivation of catalase in combination with low-concentration peroxide solutions and/or ROS generating agents to provide antibacterial effects.

In one aspect, a luminaire is provided for illumination, in which the luminaire has a normalized spectral power distribution (SPD) curve for promoting human wellness, the normalized SPD curve having the following percentage areas for the following wavelength domains, the normalized SPD curve including spectral energy in a 620 nm to 640 nm region of the SPD curve ranging from 9.5% to 10.5% of a total of an area for a normalized SPD curve; spectral energy in a 640 nm to 660 nm region of the SPD curve ranging from 7.25% to 9.8% of the total of the area of the normalized SPD curve; spectral energy in a 660 nm to 680 nm region of the SPD curve ranging from 4.8% to 7.8% of the total of the area for the normalized SPD curve; spectral energy in a 680 nm to 700 nm region of the SPD curve ranging from 2.75% to 5.5% of the total of the area for the normalized SPD curve; and a remainder of spectral energy of the total normalized SPD curve is in a 400 nm to 620 nm region area of the SPD curve.